The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are ...

Hypoxia, or low oxygen in the body, is common in solid tumors. Now, researchers have identified that an RNA molecule, EUDAL, ...

An Overland Park man is riding 700 miles on his bike to raise money for cancer research after he was diagnosed with lung ...

Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung cancer (NSCLC) and how ...

An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, ...

A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...

Treating patients with combination therapy approaches may improve survival for patients with EGFR-positive lung cancer when compared with monotherapy treamtents, such as giving Tagrisso (osimertinib) ...

Oral cancer is one of the most common head and neck cancers worldwide, with hundreds of thousands of new cases diagnosed every year. Despite advances in surgery, radiotherapy, and chemotherapy, ...

Eric K. Singhi, MD, is a thoracic oncologist at MD Anderson Cancer Center in Houston and one of Cancer Therapy Advisor’s editorial board members. He shares his top 5 presentations from the 2025 World ...

A new international study led by Mayo Clinic researchers has identified a genetic factor that may explain why some patients ...